Why Medtronic Shares Are Plunging Today?

  • Medtronic Plc's MDT Q4 FY22 sales of $8.09 billion decreased 1% Y/Y on a reported basis but increased 1% organically, missing the consensus of $8.42 billion.
  • The company has forecasted Q4 organic revenue growth of approximately 5.5%.
  • Q4 adjusted EPS of $1.52 increased 2%, missing the analyst consensus of $1.56.
  • Medtronic's heart device unit sales jumped 2% Y/Y (5% organic) to $2.96 billion. 
  • Spine & neurosurgery product segment sales remained flat Y/Y (+2%) to $2.29 billion.
  • Diabetes revenue of $597 million decreased 8% as reported and 5% organic.
  • The Medical Surgical Portfolio sales decreased 5% (-1% organic) to $2.23 billion. 
  • Dividend: The company increased its annual dividend to $2.72 per ordinary share, an 8% increase.
  • Guidance: Medtronic expects FY23 organic revenue growth of 4% to 5%. If recent foreign currency exchange rates hold, FY23 sales would be negatively affected by approximately $1.0 billion to $1.1 billion.
  • It forecasts adjusted EPS of $5.53 to $5.65, below the consensus of $5.82.
  • The company expects near-term pressure due to the supply chain, inflation, and foreign exchange challenges.
  • Price Action: MDT shares are down 4.49% at $100.80 during the premarket session on the last check Thursday.
  • Photo via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceDividendsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!